Clinical Care Options’ Post

This weekend, a small piece of my work in the CHIVE and IMPACT programs, will be presented at the American Society of Hematology annual meeting in San Diego. This work provides a blueprint on delivering clinical trial access to underserved areas, while also providing contributions to Clonal Hematopoiesis (CH) research. We hope to expand this work to additional clinics, especially those in underserved areas. We also hope our research can contribute to the development of additional clinical trials for high-risk CH and to refining care protocols for CH. https://lnkd.in/eHTeUyyT

To the pharma industry who ask for a guarantee of impact, or measure of impact of proper Patient Engagement: Let's turn it around... Show us that what you are doing works, that all your trials recruit well, and on time. Basically that your 80% failure rate is really great, and an acceptable by product in this industry... And that asking advocates for help to recruit to an impossible trial is also normal... Or ask them for extra QOL data which you 'forgot' to collect... Is this all really successful pharma business? Do some people really know what they are doing? Or is it time to listen for some real help? So no... I don't think we need to prove anything. There is enough proof that global methods don't work most of the time.

💡 Cytokines at ASCO 2024 💡 We saw a 20% increase in the number of cytokine abstracts released this year at ASCO compared to 2023, reflecting the recent upturn in the interest and investment in the cytokine space. There were a total of 152 cytokine abstracts presented, some trends in the data include: 💊 Continued growth in the fusion protein space, with half of these drugs in phase 3 clinical trials or above. 💊 Sustained interest, amongst clinical targets, in GM-CSF and IL-2, however interestingly IL-2R is emerging as a target of interest in the preclinical space, with this receptor being targeted by 44% of preclinical assets. 💊 Advanced solid tumours, followed by blood cancers like myelofibrosis were the most discussed disease indications, encouragingly a majority of solid cancer abstracts showed an absence of toxic side effects with patients not experiencing TRAEs above Gr3. Conferences are a valuable source of data from the evolving landscape, however ensuring you have taken away all information relevant to you from each, remains a challenge. See below a snippet of Beacon's cytokine post conference report. For the full abstract list drop me a message! https://lnkd.in/eCk_yDrG

"Unlock the secrets of blood health with our Clinical Research Hematology Laboratory Course! Dive into the science of blood disorders, gain hands-on experience in advanced laboratory techniques, and learn from experts in the field. Join us on this journey to enhance patient outcomes through innovative hematological research!" 😊 🙂 🙂

A healthy sense of trust at the upcoming EAPM Side Event at European Haematology congress on June 14th, Madrid... In the fast-moving area of healthcare with its cutting-edge science it is already, and will become more, vital that stakeholders collaborate openly and effectively. This should ensure that regulations and legislation covering, for example the new, smaller clinical trials required to make personalised medicine work effectively, the huge practical and ethical issues surrounding Big Data and data protection, ensuring earlier access and the necessary standards for biobank samples and in vitro devices are common, understood and enforced across the EU. Despite Member State competence in many areas, there is undoubtedly a need for common European health legislation as much as possible, but it must be the right legislation. Unfortunately, experience has shown that having separate rules in every Member State does not really work, for a variety of reasons. For example, it often leads to an R&D environment that is not competitive, slows the innovative dynamic and ultimately represents a barrier to the emergence of effective therapies for untreated disease. With more integration, collaboration, dialogue and increased trust among each and every one in the field, stakeholders can help mould the right frameworks, in the right place, at the right time. Once achieved, this will allow us all to work more quickly and more effectively towards creating a healthier – and thus wealthier – European Union. But it also has to start with a European Parliament that is on message when it comes to the issues facing its citizenry. Health is key. Please click HERE (https://lnkd.in/eVvrTjbN) to register and please click HERE to see the agenda (https://lnkd.in/egu8YKGx)

Great ESMO recap from our oncology experts. Glad my team could contribute some social media metrics and key examples. There are over 20k oncologists on social media and congresses are a huge conversation driver. Capturing their in-the-moment reactions is key for understanding perceptions around important data readouts and trends. #ESMO #ESMO24 #Oncology

✨We were able to welcome three high-profile major congresses to our premises on Exhibition Square this year: 🎯 European Stroke Organisation Conference (ESOC) 🎓 AMEE - The International Association for Health Professions Education 🩺 Annual Conference of the German Society for Hematology and Medical Oncology (DGHO) These events had a reach that extended far beyond the region 🌍, showcasing Basel as a premier destination for international gatherings. 📢 We spoke with Stefan Bonsels, Head of Basel Convention Bureau, about how Basel benefits from hosting such impactful congresses. 👉 Read the full article here: https://lnkd.in/giHZNSE5 #thisisbasel #congress #eventprofs

We’re excited to showcase data on our masked anti-CTLA-4 SAFEbody, ADG126 (muzastotug) in two posters at this year’s #SITC24! Building on strong clinical data in patients with advanced MSS CRC, these two posters provide details on how the increased therapeutic index for ADG126 can unleash efficacy & improve patient outcomes. ADG126 has best-in-class therapeutic potential, driven by our SAFEbody precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade. We are also proud the clinical abstract on our ongoing phase 1b/2 trial evaluating ADG126 in MSS CRC was selected by SITC as a Top 100 abstract out of 1439! Read more: https://loom.ly/PZ0xcVc

Earlier today we shared updated ELI-002 Phase 1 data from our AMPLIFY-201 clinical trial at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland.   Key Highlights: - Updated data include a 16.3-month median recurrence-free survival and 28.9-month median overall survival from the full study population - We observed a strong correlation between median recurrence-free survival and the strength of T cell responses - Event-driven interim analysis from our randomized Phase 2 trial is expected in H1 2025 Read the full release to learn more: https://lnkd.in/gUNr5iTr

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in the United States, accounting for 20% of all lymphoid cancers. For the 40% of patients who don’t respond to therapy, it poses a serious health challenge. Exciting results from the EPCORE NHL-2 clinical trial, led by CRI Lloyd J. Old STAR Dr. Joshua Brody at Icahn School of Medicine at Mount Sinai, offer a new hope. Published in American Society of Hematology's Blood, the study highlights the potential of combining epcoritamab (a CD3xCD20 bispecific antibody) with GemOx for relapsed/refractory DLBCL. The treatment achieved an impressive 85% overall response rate, and 61% complete response rate in patients ineligible for stem cell transplants. These findings mark a significant step forward for improving outcomes in this tough-to-treat disease. Discover: https://bit.ly/4hlwnEi #DLBCL #CancerResearch #ClinicalTrial